Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions.

ABSTRACT:

Introduction

Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic modality in oncology, offering unprecedented precision in targeting tumor cells while sparing healthy tissues. In bladder cancer, a malignancy with high recurrence rates and limited treatment options, ADCs have demonstrated remarkable efficacy by targeting specific tumor-associated antigens such as NECTIN-4 and Human Epidermal Growth Factor Receptor 2 (HER2). This review provides a comprehensive evaluation of the current landscape of ADC-based therapies for bladder cancer, focusing on their mechanisms of action, clinical efficacy, and safety profiles.

Methods

We systematically analyze 232 clinical trials from 2004 to 2025, revealing a significant upward trend in ADC research, particular

SUBMITTER: Zhang F 

PROVIDER: S-EPMC12106409 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature